Home › Hemophilia B
Pag-aaral pangklinika para sa Hemophilia B na nagre-recruit sa U.S.
12 pag-aaral para sa Hemophilia B ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Philadelphia, PA5 pag-aaral
- Sacramento, CA4 pag-aaral
- Ann Arbor, MI4 pag-aaral
- Atlanta, GA4 pag-aaral
- Houston, TX4 pag-aaral
- Los Angeles, CA4 pag-aaral
- Seattle, WA3 pag-aaral
- San Francisco, CA3 pag-aaral
- Indianapolis, IN3 pag-aaral
- Gainesville, FL3 pag-aaral
- Nashville, TN3 pag-aaral
- Greenville, NC3 pag-aaral
Ayos sa estado
- California7 pag-aaral
- Florida4 pag-aaral
- Georgia4 pag-aaral
- Indiana3 pag-aaral
- Louisiana3 pag-aaral
- Michigan6 pag-aaral
- Missouri3 pag-aaral
- New York5 pag-aaral
- North Carolina4 pag-aaral
- Ohio3 pag-aaral
- Pennsylvania6 pag-aaral
- Tennessee4 pag-aaral
- Texas4 pag-aaral
- Washington3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Okt 2, 2026 · NCT05568719A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Nagre-recruitPhase 3
Edad 1 hanggang 17 · Kalalakihan · Na-update Set 23, 2026 · NCT05611801Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Nagre-recruitPhase 3
138 Months – 206 Months · Kalalakihan · Na-update Set 16, 2026 · NCT07080905A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Nagre-recruitPhase 1/2
Edad 2 pataas · Kalalakihan · Na-update Set 11, 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT06003387SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Nagre-recruitPhase 3
Edad 6 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT04563520ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Nagre-recruitPhase 3
Edad 1 hanggang 74 · Kalalakihan · Na-update Hul 1, 2026 · NCT05145127ATHNdataset Registry
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Abr 21, 2026 · NCT06820515An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 19, 2026 · NCT06008938SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Nagre-recruitPhase 4
Edad 12 hanggang 100 · Lahat ng kasarian · Na-update Ene 12, 2026 · NCT04647227Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.